Search

Your search keyword '"Bronowicki, Jean‐Pierre"' showing total 887 results

Search Constraints

Start Over You searched for: Author "Bronowicki, Jean‐Pierre" Remove constraint Author: "Bronowicki, Jean‐Pierre"
887 results on '"Bronowicki, Jean‐Pierre"'

Search Results

1. Blood-based MASH diagnostic in candidates for bariatric surgery using mid-infrared spectroscopy: a European multicenter prospective study

3. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

5. Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study

6. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

7. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

8. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial

9. TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial

10. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

12. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)

13. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

14. Multiparametric renal function assessment in cirrhotic patients shows high prevalence of medically actionable changes in multiple modules.

15. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

16. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study

18. Large-scale screening of lipase acid deficiency in at risk population

19. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

20. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance

21. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

22. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

25. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

26. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma

27. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

28. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

29. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis

30. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

31. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

33. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

34. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma

36. Phenotypic characteristics of primary liver cancer in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study

37. Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the French prospective chief cohort

40. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

41. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

42. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

43. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma

45. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection

47. Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study

49. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

50. Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.

Catalog

Books, media, physical & digital resources